雷帕鸣一盒多少钱呢？

(Sirolomus), formerly known as Rapamycin Rapamune (RPM), is a lipophilic triene nitrogen-containing macrolide antibiotic compound produced by Streptomyces hygroscopieus isolated from soil samples of Easier Island in the Pacific by Vezina and others at the Ayerst Laboratory in Canada in 1975. It was initially used as a low-toxic antifungal drug. In 1977, it was found to have immunosuppressive effects. In 1989, RAPA began to be tried out as a new drug to treat rejection of organ transplants. Judging from the effects of animal experiments and clinical applications, it is a new immunosuppressant with good efficacy, low toxicity, and no nephrotoxicity. Compared with cyclosporine, rapamycin oral solution has a smaller dose (only 2 to 3 mg per dose), stronger anti-rejection effect, and fewer side effects. Therefore, since its launch, rapamycin has quickly become a commonly used oral immunosuppressant for organ transplant recipients around the world (especially kidney transplants). Rapamin is a serine/threonine kinase regulated by phosphoinositide-3-kinase and an mTOR (mammalian target of rapamycin) inhibitor. mTOR is a protein that controls many cellular processes, including angiogenesis and cell synthesis, making it a reasonable target for inhibiting severe vascular tumors. Recently, in a number of clinical research reports involving vascular malformations and refractory vascular tumors, rapamycin has been proven to have a significant effect in vascular and lymphoproliferative diseases.

Rapamin was approved by the FDA on May 30, 2007 for the treatment of advanced renal disease. It has entered clinical phase 4 for the treatment of mantle cell lymphoma. In terms of price, according to Medical Companion Travel, the price of Leipaming is about 1,800$/box. Since exchange rates fluctuate and prices are not fixed, please consult Medical Travel for specific prices. Rapamycin is an inhibitor of the rapamycin target protein mTOR. mTOR is a downstream protein of the PI3K/AKT pathway. This pathway is abnormally activated in a variety of tumor cells. It can control the growth of tumor cells by inhibiting the activity of mTOR and thereby inhibiting the activity of its downstream S6 ribosomal protein kinase (S6K1). In addition, it is active on its own and can be converted into rapamycin in the body to inhibit mTOR.